{
    "clinical_study": {
        "@rank": "62180", 
        "arm_group": [
            {
                "arm_group_label": "lloprost(Ventavis,BAYQ6252, 20 \u00b5g/mL)", 
                "arm_group_type": "Other", 
                "description": "Cross over design: First single inhalation of 5 \u00b5g iloprost using 20 \u00b5g/ml iloprost nebuliser solution  with the FOX nebulizer. Then single inhalation of 5 \u00b5g iloprost using 10 \u00b5g/mL iloprost nebuliser solution with the I-Neb nebulizer.  Subsequent  6 to 9 inhalations of 5 \u00b5g iloprost per day using FOX over 2 weeks, followed by 6-9 inhalations of 5 \u00b5g iloprost per day using I-Neb over 2 weeks"
            }, 
            {
                "arm_group_label": "lloprost(Ventavis,BAYQ6252, 10 \u00b5g/mL)", 
                "arm_group_type": "Other", 
                "description": "Cross over design: First single inhalation of 5 \u00b5g iloprost using 10 \u00b5g/ml iloprost nebuliser solution with the I-Neb nebulizer. Then single inhalation of 5 \u00b5g iloprost using 20 \u00b5g/mL iloprost nebuliser solution with the FOX nebulizer. Subsequent 6 to 9 inhalations of 5 \u00b5g iloprost per day using I-Neb over 2 weeks, followed by 6-9 inhalations of 5 \u00b5g iloprost per day using Fox over 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Administration of iloprost aerosol comparing two nebulizers: FOX and I-Neb"
        }, 
        "brief_title": "Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Arterial Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged \u2265 18 years\n\n          -  Current diagnosis of pulmonary hypertension (updated Dana Point Classification 1).\n\n          -  Current inhalative therapy with 5 \u00b5g iloprost using the I-Neb nebulizer\n\n          -  WHO functional class III at the time of the patient's commencement of inhalative\n             therapy with iloprost\n\n          -  Hemodynamic diagnosis of Pulmonary arterial hypertension(PAH) showing mean pulmonary\n             arterial pressure (mPAP) > 25 mmHg, pulmonary capillary wedge pressure (PCWP) or left\n             ventricular end diastolic pressure (LVEDP) < 15 mmHg and pulmonary vascular\n             resistance (PVR) > 320 dyn\u2022s\u2022cm-5\n\n          -  If non-specific types of chronic treatment for PAH are being administered: Stable\n             dosage of these for at least the 4 weeks up to screening\n\n          -  If PAH-specific drug treatments (such as endothelin receptor antagonist (ERA) or\n             phosphodiesterase-5 (PDE5) inhibitors) are being administered: Stable dosage of these\n             for at least the 3 months up to screening.\n\n        Exclusion Criteria:\n\n          -  PAH related to any other etiology, especially to pulmonary veno-occlusive disease\n             (PVOD)\n\n          -  Clinically relevant obstructive lung disease\n\n          -  Evidence of thromboembolic disease (probable pulmonary embolism) within 3 years\n             before screening\n\n          -  Cerebrovascular events within 3 months before screening\n\n          -  Atrial septostomy within the 6 months before screening\n\n          -  Severe arrhythmia, or severe coronary heart disease or unstable angina, or myocardial\n             infarction within 6 months before screening, or congenital or acquired valvular\n             defects with clinically relevant myocardial function disorders unrelated to PAH\n\n          -  Systolic blood pressure < 85 mm Hg, or uncontrolled systemic hypertension (systolic\n             BP > 160 mmHg or diastolic BP > 100 mmHg)\n\n          -  Hepatic impairment (Child Pugh B, C) or chronic renal insufficiency (creatinine > 2.5\n             mg/dl) and /or requirement of dialysis\n\n          -  Clinically relevant bleedings disorders or conditions with increased risk for\n             hemorrhages (active ulcers, trauma etc.)\n\n          -  Addition or dose change of PAH specific drug treatments such as ERA or PDE5\n             inhibitors within 3 months before screening, or addition or dose change of\n             non-specific treatments for PAH such as calcium channel blockers, nitrates,\n             digitalis, diuretics within 4 weeks before Screening, or any kind of prostanoid other\n             than those mentioned in inclusion criteria within less than 5 half-lives before\n             treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02032836", 
            "org_study_id": "16483", 
            "secondary_id": "2013-002783-12"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "lloprost(Ventavis,BAYQ6252, 20 \u00b5g/mL)", 
                    "lloprost(Ventavis,BAYQ6252, 10 \u00b5g/mL)"
                ], 
                "description": "20 \u00b5g/mL iloprost nebulizer solution, inhaled with FOX nebulizer", 
                "intervention_name": "lloprost(Ventavis,BAYQ6252, 20 \u00b5g/mL)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "lloprost(Ventavis,BAYQ6252, 20 \u00b5g/mL)", 
                    "lloprost(Ventavis,BAYQ6252, 10 \u00b5g/mL)"
                ], 
                "description": "10 \u00b5g/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer", 
                "intervention_name": "lloprost(Ventavis,BAYQ6252, 10 \u00b5g/mL)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Iloprost"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 15, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "state": "Steiermark", 
                        "zip": "8036"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gie\u00dfen", 
                        "country": "Germany", 
                        "state": "Hessen", 
                        "zip": "35392"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Germany"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-center, Open-label, Randomized Cross-over Study to Compare the Acute Tolerability and Pharmacokinetics of BAYQ6256 (Iloprost; Ventavis) Inhalation Using the I-Neb Nebulizer and the FOX Nebulizer in Patients With Pulmonary Arterial Hypertension", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Austria: Federal Office for Safety in Health Care"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of patients with a meaningful maximum increase (i.e. >=25%) in heart rate AND/OR a meaningful maximum decrease (i.e. >=20%) in systolic blood pressure within the 30 minutes after the start of inhalation", 
            "safety_issue": "Yes", 
            "time_frame": "multiple measurements within 30 minutes after iloprost inhalation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02032836"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum change in systolic, diastolic and mean arterial blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to multiple BP measurements within 2 hours after iloprost inhalation"
            }, 
            {
                "measure": "Maximum change in heart rate within the 30 minutes following inhalation", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to multiple HR measurements within 30 minutes after iloprost inhalation"
            }, 
            {
                "measure": "Maximum change in oxygen saturation within the 30 minutes following inhalation using finger pulse oxymetry", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to multiple measurements within 30 minutes after iloprost inhalation"
            }, 
            {
                "measure": "AUC (area under the plasma concentration curve of BAYQ6256 from zero to infinity)", 
                "safety_issue": "No", 
                "time_frame": "Multiple timepoints up to 1 hour"
            }, 
            {
                "measure": "Maximum observed drug concentration in plasma after single dose administration", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sampling within 60 minutes after Ventavis inhalation and subsequent iloprost bioanalytics"
            }, 
            {
                "measure": "Time to reach maximum drug observed concentration in plasma after single dose", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sampling within 60 minutes after Ventavis inhalation and subsequent iloprost bioanalytics"
            }, 
            {
                "measure": "half-life (associated with terminal slope)", 
                "safety_issue": "No", 
                "time_frame": "Multiple blood sampling within 60 minutes after Ventavis inhalation and subsequent iloprost bioanalytics"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}